Value of serum CYFRA21-1 in the detection of curative effects on advanced NSCLC
10.3760/cma.j.issn.1008-6706.2014.14.028
- VernacularTitle:血清细胞角蛋白19片段检测用于晚期非小细胞肺癌疗效评价的价值
- Author:
Yangui HUANG
;
Ming CAO
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Tumor marker;
Keratins
- From:
Chinese Journal of Primary Medicine and Pharmacy
2014;(14):2146-2148
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the siginicance of evaluation of chemotherapy the changes of serum concentration of CYFRA21-1 application in patients with advanced non-small cell lung cancer (NSCLC).Methods Enzyme linked immunosorbent assay ( ELISA) was used to analyze of 86 cases of advanced NSCLC in the serum of the patients after first-line chemotherapy(gemcitabine +cisplatin) difference between the changes of CYFRA21-1 con-centration in serum before and after chemotherapy ,and 42 cases of normal healthy control CYFRA 21-1 concentration in human serum were analyzed .Results Compared with healthy controls ,serum concentrations of CYFRA 21-1 in pa-tients with advanced NSCLC increased significantly [(1.98 ±1.17)μg/L vs (17.36 ±13.28)μg/L,t=12.56,P<0.05],and the concentration of CYFRA21-1 in serum of patients with lung squamous cell carcinoma was significantly higher than that in patients with lung adenocarcinoma [(25.47 ±15.31)μg/L vs (17.36 ±13.28)μg/L, t=5.84, P<0.05] .In addition to first-line chemotherapy in patients with NSCLC patients ,the serum concentration of CY-FRA21-1 significantly lower than before chemotherapy and after chemotherapy ,the first-line chemotherapy drug was invalid or CYFRA21-1 concentration in serum of patients with chemotherapy resistance in before and after the change is not obvious ,even there was a trend of rising .Conclusion Serum CYFRA21-1 can be used as the curative effect of chemotherapy in patients with advanced NSCLC effective evaluation index of early .
